Coartem®: a decade of patient-centric malaria management
Coartem®: a decade of patient-centric malaria management
复制标题
DOI：
10.1586/eri.12.51
复制
发表时间：
2012-06-01
影响因子：
5.7
通讯作者：
Grueninger, Heiner
中科院分区：
文献类型：
--
作者：
Hamed, Kamal;Grueninger, Heiner
采用以青蒿素为基础的联合疗法以及其他疟疾控制策略，在减轻许多疟疾流行国家的疟疾负担方面发挥了重要作用。基于青蒿素的联合疗法蒿甲醚-本芴醇（AL；复方蒿甲醚 (R)，瑞士巴塞尔诺华制药公司）十多年来一直表现出高疗效和安全性。目前在大多数撒哈拉以南非洲国家被用作一线或二线治疗，其广泛使用得到了非洲迄今为止缺乏寄生虫耐药性报道的认可。 AL 专注于患者需求，为婴儿和儿童提供量身定制的配方以及促进依从性的包装解决方案。为了消除疟疾，使用 AL 的创新策略（例如治疗无症状携带者）将会引起人们的兴趣。 AL 有潜力继续在拯救生命方面发挥重要作用。
The adoption of artemisinin-based combination therapy, together with other malaria control strategies, has played a significant role in reducing the burden of malaria in many endemic countries. The artemisinin-based combination therapy artemether-lumefantrine (AL; Coartem (R), Novartis Pharma AG, Basel, Switzerland) has demonstrated consistently high efficacy and safety for over a decade. Currently deployed as a first- or second-line treatment in most sub-Saharan African countries, its extensive use is endorsed by a lack of reported parasite resistance in Africa to date. With a focus on patient needs, AL offers a tailored formulation for infants and children, and packaging solutions to promote adherence. Working towards malaria elimination, innovative strategies using AL, such as treatment of asymptomatic carriers, will be of interest. AL has the potential to continue playing an important role in saving lives.